Skip to content
Screener

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Amgen logo
AmgenAMGN
$937M-15.5%
WHW
Whitehawk TherapeuticsWHWK
$11.06M-9.9%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$30.43M+10.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$44.29M-58.8%
Eikon Therapeutics, Inc. logo
Eikon Therapeutics, Inc.EIKN
$300.16M

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.49B+68.5%
Enterprise value$3.36B+69.4%
P/S15×+10.3×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206357
Line itemMarch 31, 2026December 31, 2025
Operating lease liabilities, current350339
Total current liabilities64,83158,815
Long-term operating lease liabilities28,25027,575
Total liabilities93,08186,390
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 87,856,154 and 87,796,561 shares issued and outstanding as of March 31, 2026 and December 31, 202599

Item 1. Financial Statements (UNAUDITED).

FAQ

What is IDEAYA Biosciences, Inc.'s total liabilities?
IDEAYA Biosciences, Inc. (IDYA) reported total liabilities of $93.08M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s total liabilities changed year-over-year?
IDEAYA Biosciences, Inc.'s total liabilities increased by 21.7% year-over-year, from $76.51M to $93.08M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s total liabilities?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s total liabilities has grown at a -2.9% compound annual growth rate (CAGR), from $100M to $86.39M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about IDEAYA Biosciences, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude